20/20 BioLabs Reports Strong FY2025 Results, Secures Funding, and Eyes Growth in 2026

Summary of Key Developments

• FY2025 revenue grew 17% to \$2.0 million, driven by the OneTest MCED blood test and CLIAx streams.
• Gross profit surged 68%, with gross margin expanding 900 basis points to 29.6%.
• Operating expenses reduced by 35%, supporting a 33% improvement in net loss to (\$3.7) million.
• Cash used in operations fell to \$1.9 million, with a year-end cash balance of \$1.0 million.
• Raised \$5.0 million in a private placement in February 2026, enabling access to up to \$40 million in capital.
• State funding: \$520,000 awarded by Maryland for firefighter cancer screenings, representing a 225% increase in tests funded over the prior year.
• Recent Nasdaq listing under ticker “AIDX” and legislative tailwinds for MCED reimbursement.
• Launch of OneTest for Longevity, integrating IBM AI and new partnerships for chronic disease risk assessment.

Detailed Financial Performance & Operational Highlights

Revenue and Profitability

20/20 BioLabs delivered robust financial results for the year ended December 31, 2025. Revenue increased 17% to \$2.0 million, up from \$1.8 million in 2024, primarily due to growth in its OneTest multi-cancer early detection (MCED) blood test and CLIAx revenue streams. Gross profit soared 68% to \$0.6 million, with gross margin improving significantly to 29.6% from 20.6% in the prior year, reflecting a more favorable revenue mix and higher-margin products.

Cost controls were a central theme, as operating expenses dropped by 35% to \$3.9 million, mainly due to lower digital marketing spend and a reduction in R&D expenses following the completion of two key studies in 2024. As a result, the company’s net loss narrowed by 33% to (\$3.7) million, compared to (\$5.6) million in 2024. Net cash used in operating activities also improved, falling to \$1.9 million from \$2.6 million the prior year.

Cash, Funding, and Balance Sheet

The company ended 2025 with \$1.0 million in cash, down from \$1.8 million at the previous year-end. Crucially, on February 19, 2026, 20/20 BioLabs secured \$5.0 million via a private placement under a preferred purchase agreement, which enables the company to raise up to \$40 million in multiple tranches, subject to performance milestones. This funding strengthens the company’s balance sheet and supports ongoing growth initiatives.

Total assets as of December 31, 2025, stood at \$4.1 million versus \$3.6 million a year earlier. Total liabilities increased to \$4.2 million from \$2.1 million, driven by new convertible notes, derivative liabilities, and higher accounts payable reflecting company growth and financing activities. The company had a small shareholders’ deficit of (\$19,225) compared to positive equity of \$1.5 million at the end of 2024, due largely to cumulative losses.

New Contracts, Partnerships, and Product Launches

• Maryland State Funding for Firefighter Screenings: 18 Maryland fire departments received \$520,000 from the Maryland Department of Health to administer OneTest MCED blood tests, representing a 225% increase in the number of tests funded by this program over the previous year. This state-backed initiative underscores growing support for OneTest and could become a significant revenue driver in 2026.
• Product Innovation: The company launched OneTest for Longevity, a new blood test and chronic disease risk assessment/management solution developed with IBM’s watsonx.ai platform. This product tracks chronic inflammation biomarkers linked to diseases such as diabetes, dementia, and cardiovascular disease, and provides AI-driven, personalized dietary recommendations.
• Strategic Partnerships: An exclusive U.S. license agreement with ROKIT Healthcare enables 20/20 BioLabs to integrate advanced chronic kidney disease (CKD) prediction technology into its Longevity Test Program. Discussions are ongoing with ROKIT to expand this offering into the East Asian market.

Regulatory and Market Tailwinds

A major legislative development in February 2026 is the passage of the Medicare Multi-Cancer Early Detection Screening Act, which establishes a clear pathway for Medicare reimbursement of MCEDs by 2028. This could significantly expand the addressable market for OneTest for Cancer, and the company intends to seek Medicare coverage for this product.

The company commenced trading on the Nasdaq Capital Market under the ticker “AIDX” on February 19, 2026, increasing its visibility and potentially broadening its investor base.

Management Outlook

CEO Jonathan Cohen expressed confidence that 2026 could be a breakout year, fueled by strong demand in markets such as firefighting, veterans’ health, occupational health, and self-insured employers. Deferred revenue of \$0.5 million at year-end provides visibility into near-term revenues as the company fulfills its obligations.

The company is also expanding direct-to-consumer sales efforts, especially with the Longevity product now available for purchase. Management believes that improving gross margins, a lower operating cost base, and new capital access position 20/20 BioLabs for substantial growth and a path toward profitability.

Key Points for Shareholders & Potential Share Price Impacts

• Significant revenue and margin growth demonstrate the company’s ability to scale and improve profitability, which are positive signals for investors.
• State and potentially federal reimbursement tailwinds (notably, the new Medicare pathway for MCEDs) could unlock substantial new revenue streams.
• The recent \$5.0 million capital raise (with access to up to \$40 million) improves liquidity and supports growth plans, reducing financing risk.
• The Nasdaq listing under ticker AIDX enhances visibility, liquidity, and may attract new institutional investors.
• New partnerships and product launches (with IBM and ROKIT Healthcare) extend the company’s technology leadership and open new market opportunities.
• Continued operating losses and a shareholders’ deficit are risks, but the improved trend and funding access mitigate near-term concerns.

Conclusion

With accelerating revenue, improving margins, a strong pipeline of contracts (notably in the public sector), new product launches, and recent substantial funding, 20/20 BioLabs appears well-positioned for significant growth in 2026. The passage of Medicare reimbursement legislation for MCEDs, in particular, could be a game-changer for the company’s long-term prospects. However, investors should remain mindful of ongoing operating losses and execution risks as the company scales.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a professional advisor before making any investment decisions. Past performance is not indicative of future results. Forward-looking statements are subject to risks and uncertainties as discussed in the company’s SEC filings.

View 20/20 Biolabs, Inc. Historical chart here